The abstract is read at the publisher; the summary is JClub's.
In the DECISION-CTO randomized trial, initial CTO-PCI versus no CTO-PCI produced similar 10-year primary endpoint rates (33.9% vs 37.4%) in 804 patients.
- Why it matters: Long-term outcomes of CTO-PCI are uncertain, creating a need to know whether starting with CTO-PCI improves survival or reduces major events beyond short-term follow-up.
- What they did: Across 19 centers in 5 Asian countries, 834 patients were randomized to initial CTO-PCI or no CTO-PCI with guideline-directed medical therapy, and 10-year outcomes were analyzed in a modified intention-to-treat group of 804.
- The result: At 10 years, the primary composite occurred in 134 vs 138 patients (P = 0.32), all-cause death was 12.7% vs 16.5% (P = 0.16), and wide confidence intervals limit definitive benefit or harm conclusions.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.